title: Use of nonprescription weight loss products: results from a multistate survey.
abstract: BACKGROUND
  Lifestyle changes to lose weight can be difficult; hence, both prescription and nonprescription diet products are appealing. Usage patterns of the nonprescription products phenylpropanolamine (PPA) and ephedra are of particular interest because of recent safety concerns.
  
  
  OBJECTIVE
  To estimate the prevalence of overall and specific nonprescription weight loss product use by demographic characteristics, prescription diet pill use, diabetic status, and lifestyle choices.
  
  
  METHODS
  The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1998 in 5 states: Florida, Iowa, Michigan, West Virginia, and Wisconsin.
  
  
  METHODS
  Population-based sample of 14 679 noninstitutionalized adults 18 years or older.
  
  
  METHODS
  Prevalence of nonprescription weight loss product use in 1996-1998.
  
  
  RESULTS
  Seven percent reported overall nonprescription weight loss product use, 2% reported PPA use, and 1% reported ephedra product use. Overall use was especially common among young obese women (28.4%). Moreover, 7.9% of normal-weight women reported use. There was no difference in nonprescription weight loss product use by daily consumption of fruits and vegetables; however, more users than nonusers reported being physically active (for those who exercised >/=30 minutes 5 times per week, odds ratio, 1.5; 95% confidence interval, 1.2-2.0). Among prescription weight loss product users, 33.8% also took nonprescription product.
  
  
  CONCLUSIONS
  With increasing rates of obesity, nonprescription product use is likely to increase. Clinicians should know about their patients' use of both prescription and nonprescription weight loss products.
authors.affiliation: Division of Nutrition and Physical Activity, 4770 Buford Hwy NE, MS K-26, Atlanta, GA 30341-3717, USA. Hblanck@cdc.gov
authors.forename: H M
authors.initials: HM
authors.lastname: Blanck
authors.forename: L K
authors.initials: LK
authors.lastname: Khan
authors.forename: M K
authors.initials: MK
authors.lastname: Serdula
mesh_terms: D000328:Adult; D001067:Appetite Depressants; D015992:Body Mass Index; D003920:Diabetes Mellitus; D019587:Dietary Supplements / Q000706:statistics & numerical data*; D004809:Ephedrine; D005260:Female; D005431:Florida / Q000453:epidemiology; D015438:Health Behavior; D006801:Humans; D007484:Iowa / Q000453:epidemiology; D008019:Life Style; D008297:Male; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D004366:Nonprescription Drugs; D009765:Obesity; D010665:Phenylpropanolamine; D015995:Prevalence; D012651:Self Medication / Q000706:statistics & numerical data / Q000639:trends*; D014481:United States / Q000453:epidemiology; D015431:Weight Loss; D014903:West Virginia / Q000453:epidemiology; D014922:Wisconsin / Q000453:epidemiology
chemical_list: D001067:Appetite Depressants; D004366:Nonprescription Drugs; D010665:Phenylpropanolamine; D004809:Ephedrine